Vaccine description | |
---|---|
Target | SARS-CoV-2 |
Vaccine type | Inactivated |
Clinical data | |
Routes of administration | Intramuscular |
Part of a series on the |
COVID-19 pandemic |
---|
![]() |
|
Medical response |
|
![]() |
KD-414 is a COVID-19 vaccine candidate developed by Japanese biotechnology company KM Biologics Co. [1] [2] [3] Results of a phase 1/2 clinical trial for this vaccine were released as a preprint in June 2022. [4]
Development | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Classes | |||||||||||
Administration | |||||||||||
Vaccines |
| ||||||||||
Inventors/ researchers | |||||||||||
Controversy | |||||||||||
Related | |||||||||||
|
![]() | This article about COVID-19 vaccines is a stub. You can help Wikipedia by expanding it. |
![]() | This article about vaccines or vaccination is a stub. You can help Wikipedia by expanding it. |